vs
Apellis Pharmaceuticals, Inc.（APLS）与Douglas Elliman Inc.（DOUG）财务数据对比。点击上方公司名可切换其他公司
Douglas Elliman Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$245.4M vs $199.9M），Douglas Elliman Inc.净利率更高（27.9% vs -29.5%，领先57.4%），Douglas Elliman Inc.同比增速更快（0.9% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-14.7M），过去两年Douglas Elliman Inc.的营收复合增速更高（10.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Douglas Elliman Inc.是美国领先的住宅房地产经纪企业，提供高端房产买卖、租赁、物业管理及相关咨询服务，核心业务覆盖纽约、加州、佛罗里达、得克萨斯等都会区，主要服务高净值客户群体。
APLS vs DOUG — 直观对比
营收规模更大
DOUG
是对方的1.2倍
$199.9M
营收增速更快
DOUG
高出6.8%
-5.9%
净利率更高
DOUG
高出57.4%
-29.5%
自由现金流更多
APLS
多$411.0K
$-14.7M
两年增速更快
DOUG
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $245.4M |
| 净利润 | $-59.0M | $68.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 27.3% |
| 净利率 | -29.5% | 27.9% |
| 营收同比 | -5.9% | 0.9% |
| 净利润同比 | -62.2% | 1243.4% |
| 每股收益（稀释后） | $-0.40 | $0.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSDOUG
| Q4 25 | $199.9M | $245.4M | ||
| Q3 25 | $458.6M | $262.8M | ||
| Q2 25 | $178.5M | $271.4M | ||
| Q1 25 | $166.8M | $253.4M | ||
| Q4 24 | $212.5M | $243.3M | ||
| Q3 24 | $196.8M | $266.3M | ||
| Q2 24 | $199.7M | $285.8M | ||
| Q1 24 | $172.3M | $200.2M |
净利润APLSDOUG
| Q4 25 | $-59.0M | $68.6M | ||
| Q3 25 | $215.7M | $-24.7M | ||
| Q2 25 | $-42.2M | $-22.7M | ||
| Q1 25 | $-92.2M | $-6.0M | ||
| Q4 24 | $-36.4M | $-6.0M | ||
| Q3 24 | $-57.4M | $-27.2M | ||
| Q2 24 | $-37.7M | $-1.7M | ||
| Q1 24 | $-66.4M | $-41.5M |
营业利润率APLSDOUG
| Q4 25 | -25.6% | 27.3% | ||
| Q3 25 | 48.7% | -4.1% | ||
| Q2 25 | -18.6% | -2.0% | ||
| Q1 25 | -50.0% | -2.1% | ||
| Q4 24 | -12.3% | -6.7% | ||
| Q3 24 | -24.0% | -2.8% | ||
| Q2 24 | -14.7% | -1.3% | ||
| Q1 24 | -36.0% | -20.7% |
净利率APLSDOUG
| Q4 25 | -29.5% | 27.9% | ||
| Q3 25 | 47.0% | -9.4% | ||
| Q2 25 | -23.6% | -8.4% | ||
| Q1 25 | -55.3% | -2.4% | ||
| Q4 24 | -17.1% | -2.5% | ||
| Q3 24 | -29.2% | -10.2% | ||
| Q2 24 | -18.9% | -0.6% | ||
| Q1 24 | -38.5% | -20.7% |
每股收益（稀释后）APLSDOUG
| Q4 25 | $-0.40 | $0.80 | ||
| Q3 25 | $1.67 | $-0.29 | ||
| Q2 25 | $-0.33 | $-0.27 | ||
| Q1 25 | $-0.74 | $-0.07 | ||
| Q4 24 | $-0.30 | $-0.06 | ||
| Q3 24 | $-0.46 | $-0.33 | ||
| Q2 24 | $-0.30 | $-0.02 | ||
| Q1 24 | $-0.54 | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $115.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $183.9M |
| 总资产 | $1.1B | $444.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSDOUG
| Q4 25 | $466.2M | $115.5M | ||
| Q3 25 | $479.2M | $143.0M | ||
| Q2 25 | $370.0M | $136.3M | ||
| Q1 25 | $358.4M | $136.8M | ||
| Q4 24 | $411.3M | $145.5M | ||
| Q3 24 | $396.9M | $151.4M | ||
| Q2 24 | $360.1M | $92.9M | ||
| Q1 24 | $325.9M | $91.5M |
总债务APLSDOUG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSDOUG
| Q4 25 | $370.1M | $183.9M | ||
| Q3 25 | $401.2M | $115.1M | ||
| Q2 25 | $156.3M | $137.6M | ||
| Q1 25 | $164.2M | $158.2M | ||
| Q4 24 | $228.5M | $162.2M | ||
| Q3 24 | $237.1M | $173.6M | ||
| Q2 24 | $264.3M | $196.9M | ||
| Q1 24 | $266.7M | $195.1M |
总资产APLSDOUG
| Q4 25 | $1.1B | $444.4M | ||
| Q3 25 | $1.1B | $480.6M | ||
| Q2 25 | $821.4M | $489.0M | ||
| Q1 25 | $807.3M | $493.9M | ||
| Q4 24 | $885.1M | $493.9M | ||
| Q3 24 | $901.9M | $502.7M | ||
| Q2 24 | $904.5M | $463.9M | ||
| Q1 24 | $831.9M | $461.1M |
负债/权益比APLSDOUG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-14.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-14.7M |
| 自由现金流率自由现金流/营收 | -7.1% | -6.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | -0.21× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-17.2M |
8季度趋势，按日历期对齐
经营现金流APLSDOUG
| Q4 25 | $-14.2M | $-14.4M | ||
| Q3 25 | $108.5M | $5.5M | ||
| Q2 25 | $4.4M | $642.0K | ||
| Q1 25 | $-53.4M | $-5.6M | ||
| Q4 24 | $19.4M | $-9.0M | ||
| Q3 24 | $34.1M | $9.0M | ||
| Q2 24 | $-8.3M | $1.3M | ||
| Q1 24 | $-133.0M | $-27.3M |
自由现金流APLSDOUG
| Q4 25 | $-14.3M | $-14.7M | ||
| Q3 25 | $108.3M | $4.7M | ||
| Q2 25 | $4.4M | $-575.0K | ||
| Q1 25 | $-53.4M | $-6.7M | ||
| Q4 24 | $19.3M | $-10.2M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | $-8.4M | $432.0K | ||
| Q1 24 | $-133.3M | $-29.4M |
自由现金流率APLSDOUG
| Q4 25 | -7.1% | -6.0% | ||
| Q3 25 | 23.6% | 1.8% | ||
| Q2 25 | 2.5% | -0.2% | ||
| Q1 25 | -32.0% | -2.6% | ||
| Q4 24 | 9.1% | -4.2% | ||
| Q3 24 | — | 2.9% | ||
| Q2 24 | -4.2% | 0.2% | ||
| Q1 24 | -77.3% | -14.7% |
资本支出强度APLSDOUG
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 1.0% |
现金转化率APLSDOUG
| Q4 25 | — | -0.21× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
